---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-017244"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:45:26.421733+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lyell Q4/FY25 net loss $274.4M; Phase 3 PiNACLE-H2H begins; cash $247.2M

## Summary
- FY25 net loss $274.4M vs $343.0M in FY24; Q4 net loss $140.7M (incl. $66.3M IPR&D for LYL273).
- Ronde-cel Phase 3 PiNACLE-H2H (2L LBCL) started dosing; Phase 1/2 PiNACLE 3L+ data shown at ASH 2025.
- LYL273 (GCC-targeted CAR-T) Phase 1 dosed 7 more mCRC patients; no DLT; dose escalated to Level 3.
- Smital Shah appointed CFO and Business Officer in March 2026; $50M equity tranche closed on milestone.
- Cash $247.2M at year-end 2025 (excl. $50M tranche); runway into Q2 2027.

## SEC filing metadata
- accession: 0001628280-26-017244
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/0001628280-26-017244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-017244
- JSON: https://secwatch.observer/filing/0001628280-26-017244.json
- Plain text: https://secwatch.observer/filing/0001628280-26-017244.txt

## Key facts
- Earnings Releases
  Lyell Immunopharma, Inc. reported financial results for the quarter and full year ended December 31, 2025.
  - Period: the quarter and full year ended December 31, 2025
  - Result: reported results
  source text: On March 12, 2026, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/0001628280-26-017244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.